Dossier assessment
Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Project details
- Project no.
- A17-14
- Commission
- Commission awarded on 31.03.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14
Status: Commission completed
-
Dossier assessment
Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed